Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure-Reference-Cited by-同舟云学术

Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure

Published:2013-03 Issue:4 Volume:73 Page:371-381
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Garnock-Jones Karly P.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-013-0031-5.pdf

Reference22 articles.

1. Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16(3):888–97.

2. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30(7):631–7.

3. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85(1):1–14.

4. Banerjee D. Recent advances in the pathobiology of Hodgkin’s lymphoma: Potential impact on diagnostic, predictive, and therapeutic strategies. Adv Hematol. 2011. doi: 10.1155/2011/439456 .

5. Dunleavy K, Piekarz RL, Zain J, et al. New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies. Clin Cancer Res. 2010;16(23):5608–17.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugates for cancer therapy: An up-to-date review on the chemistry and pharmacology;Bioconjugated Materials Part 2 Applications in Drug Delivery, Vaccine Formulations and Important Conjugates for Cancer Therapy;2023

2. Marine Derived Pharmaceuticals in Biomedical Research: Current Developments and Future Prospects;Marine Bioactive Molecules for Biomedical and Pharmacotherapeutic Applications;2023

3. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination;Journal of Hematology & Oncology;2020-04-15

4. Current Development of Monoclonal Antibodies in Cancer Therapy;Current Immunotherapeutic Strategies in Cancer;2019-09-01

5. Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo;Journal of Medicinal Chemistry;2019-02-08